NexMed Impotence Remedy Stalled At FDA
Written by Richard Simmons | Thursday, 24 July 2008 | There are 0 comments
different from the erectile dysfunction drugs Viagra, Cialis & Levitra
Bad news for the company NexMed is that its application for an experimental erectile dysfunction treatment as been rejected by the Food & Drug Administration. The particular treatment in question was to be a topically applied cream which would boost erectile function in men. This would make it completely different from the erectile dysfunction drugs Viagra, Cialis and Levitra which are all administered orally.
The Food & Drug Administration issued a non-approvable letter which noted potential health issues which had cropped up in testing done on laboratory mice. NexMed said that while they were disappointed by the Food & Drug Administration decision the issues were potentially resolvable and they would be meeting with FDA officials to plan the way forward.
On the news that the NexMed erectile dysfunction remedy was encountering problems at the FDA its share price fell by around a quarter but later rose slightly again in the regular trading session.
The erectile dysfunction medications Viagra, Cialis and Levitra have been extremely successful and extremely lucrative for the companies that made them however there is still a market for other erectile dysfunction remedies which do not work as PDE-5 inhibitors. These types of erectile dysfunction medications sometimes cause unpleasant side effects in some users, and also cannot be used by men who are taking medications called nitrates for heart problems as they interact negatively.
A topically applied erectile dysfunction treatment such as the one being researched by NexMed could potentially be a financial blockbuster for the company. NexMed is just one of many companies investing huge amounts of money in alternative remedies to cure erectile dysfunction in men. While the rewards for discovering a new erectile dysfunction remedy are huge the risks are great too, and many pharmaceutical organisations have given up or run out of money when researching and developing new treatments.
